Casi Pharmaceuticals signs license assignment agreement for Folotyn in China

Casi Pharmaceuticals (CASI) announced the execution of an Assignment Agreement with Mundipharma International, Mundipharma Medical Company and Acrotech Biopharma for the commercialization of Folotyn in the People’s Republic of China. Folotyn is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This product was approved by both the FDA and China’s National Medical Products Administration for PTCL. Casi will assume MICL’s rights and obligations with respect to the commercialization of Folotyn in China.